Background
2-year control rates | |||||||||
---|---|---|---|---|---|---|---|---|---|
Author reference) | n | risk level | % LRC | % DFS | % OAS | % high risk | pRT technique | pRT dose | cc ChTh |
Aug et al [5] | 151 | HR | ~72 | na | ~60 | 100% | 3dcrt | 63 Gy | no |
62 | LR, IR | ~95 | na | ~90 | 0% | 3dcrt | LR: no RT, IR: 57.6 Gy | no | |
Cooper et al [4] | 228 | HR | ~83 | ~55 | ~65 | 100% | 3dcrt | 60–66 Gy in 30–33 f | yes |
231 | HR | ~72 | ~50 | ~55 | 100% | 3dcrt | 60–66 Gy in 30–33 f | no | |
Bernier et al [3] | 167 | HR | ~82 | ~67 | ~75 | > 60% | 3dcrt | 66 Gy in 33 f | yes |
167 | HR | ~70 | ~48 | ~61 | > 60% | 3dcrt | 66 Gy in 33 f | no | |
Bachaud et al [2] | 39 | HR | 79 | 65 | 75 | 100% | 3dcrt | NA | yes |
44 | HR | 59 | 41 | 44 | 100% | 3dcrt | NA | no | |
Porceddu et al [13] | 47 | HR | ~73 | ~56 | ~62 | 100% | 3dcrt | mean 60 Gy (50–66) | yes |
own
| 60 | HR | 92 | 90 | 81 | 100% | IMRT | 60–70 Gy in 27–35 f | most (>80%) |
11 | IR | 100 | 90 | 90 | 0% | IMRT | 60–70 Gy in 27–35 f | most (>80%) |
Author, ref | (year) | n pIMRT (dIMRT) | HNC subsites | T3/4, rec, OCC | pIMRT dose | Chemotherapy | 2-y L(R)C | median FU |
---|---|---|---|---|---|---|---|---|
Lee et al [15] |
(2003)
| 43 (107) | all | 53, 0, 2% | 66 Gy | 35% of pIMRT | 83% LC | 25 (6–78) |
Chao et al [9] |
(2004)
| 74 (52) | all | 52, 0, 12% | ~68 Gy (+/-4.7) | none of pIMRT | 90% LRC | 26 (12–55) |
Feng et al [10] |
(2005)
| 86 (72) | all but NPC/SNC | 90 lll/lV, 3, 23% | ~70 Gy (66–76) | 12% of all | ~85% LRC | 36 (6–127) |
Yao et al [12] |
(2005)
| 51 (100) | all | 53, 0, 19% | 64–66 Gy | none of pIMRT | ~92% LC | 18 (2–60) |
own
|
(2006)
| 71 (230) | all SCC | 25, 18, 31% | ~66 Gy (60–70) | 83% of pIMRT | 95% LC | 17.6 (2–48) |
91% NC |
Results
factors | n |
---|---|
gender
| 61 m : 10 f |
age
| 59 (38–85) |
diagnosis
| |
oropharynx
| 32 |
oral cavity
| 22 |
hypopharynx
| 7 |
sinus
| 3 |
larynx
| 6 |
unknown, N+
| 1 |
T stages
| |
Tx | 1 |
T1 | 18 |
T2 | 21 |
T3 | 6 |
T4 | 12 |
recurrence * | 13 |
N stages
| |
N0 | 15 |
N1 | 4 |
N2a-b | 43 |
N2c | 6 |
N3 | 3 |
concomitant CT **
| 59 (83%) |
median/mean FU
| 17.6/19 months |
Adverse factors | n patients [na] |
---|---|
ECE nodal
| 33 [1] |
>1 nodal group
| 30 [2] |
>/= 2 pos LN
| 34 [2] |
> 3 cm LN
| 19 [4] |
OCC
| 22 [0] |
R1
| 51 [5] |
PNI
| 11 [6] |
Treatment times
postoperative SIB-IMRT schedules | |||||
---|---|---|---|---|---|
n patients | PTV1 | PTV2 | PTD PTV1/PTV2 (Gy) | fractionation | TRT (days) |
47
| 30–35 × 2.0 Gy | 30–35 × 1.64–1.8 Gy | 60–70/48–56 | 5/w | 38–47 |
16
| 30–33 × 2.11 Gy | 30–33 × 1.64 Gy | 63.3–69.6/49.2–54 | 5/w | 40–45 |
7
| 27–30 × 2.2 | 27–30 × 1.8 Gy | 59.4–66/48.6–54 | 5/w | 37–40 |
1
| 27 × 2.3 (LN), 2.2 Gy | 27 × 1.8 Gy | 62.1, 59.4/48.6 | 5/w | 37 |